Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Mepolizumab, Spirometry; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 28
States / cities: La Jolla, California • Newport Beach, California • Aurora, Colorado + 24 more

Conditions: Lung Cancer
Interventions: Biopsy of the major carinal area, Biopsy of abnormal & suspicious areas of the bronchial tree, Evaluation of the tumor for DNA mutations, Bronchoalveolar Lavage (BAL) for cytokine analysis, Correlation of flow cytometric & RT PCR for TNM stage, Analysis of lymph nodes; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2050
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: ARDS, Sepsis, Pneumonia
Interventions: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan; Other · Procedure · Radiation
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 20
States / cities: Fresno, California • Palo Alto, California • San Francisco, California + 12 more

Conditions: Gastroparesis, Lung Transplant; Complications
Interventions: High Resolution Electrogastography; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Houston, Texas • Charlottesville, Virginia

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate; Procedure · Biological · Drug + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 25 Years
Enrollment: 5,951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 203
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more

Conditions: Colitis Ulcerative
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 27
States / cities: Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more

Conditions: Type 2 Diabetes Mellitus
Interventions: GlucoType; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Cleidocranial Dysostosis
Interventions: observational; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hemoglobinopathies, Hemolysis, Iron Deficiency and Overload, Anemias
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year and older
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Preterm Birth, Inflammation, Stress, Mental Health Issue
Interventions: Cognitive Challenge; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
Interventions: BXCL701 plus Pembrolizumab, BXCL701 monotherapy; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more

Conditions: Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
Interventions: Hyperpolarized 129 Xenon; Combination Product
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Asthma, Severe Persistent Asthma
Interventions: Triamcinolone Acetonide; Drug
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 6 Years and older
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Choreatic Disorder
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: Standard Lifestyle Intervention (SLI) program, Phenotype-tailored Lifestyle Intervention (PLI) program; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity, Inflammation
Interventions: Not listed
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Davis, California

Conditions: Alcohol Drinking
Interventions: Alcohol Cue Reactivity and Laboratory Alcohol Administration Paradigm; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 21 Years to 25 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: HIV Infections
Interventions: Efavirenz, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 46
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Ovarian Cancer
Interventions: PET/CT Scan, MRI; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Harrison, New York • New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK5784283, Placebo, Standard of care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Doral, Florida • Lake Charles, Louisiana

Conditions: Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 25 Years to 50 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemophilia A, Severe Hemophilia A
Interventions: rVIII-SingleChain; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: Male only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 9
States / cities: San Diego, California • Aurora, Colorado • Hartford, Connecticut + 6 more

Conditions: Spinal Cord Injuries, Chronic Pain
Interventions: Various Stimulation Patterns; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Enteric Hyperoxaluria, Hyperoxaluria
Interventions: C-13 labeled oxalate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 4 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Detection of Genetic Markers of Lung Cancer

The APS Phenotyping Study

HR-EGG in Medically Refractory Gastroparesis

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Personalizing Self-management in Diabetes - Pilot Study

Cleidocranial Dysplasia (CCD): From Genotype to Phenotype and Considerations for Care

Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes

Stress Phenotypes and Preterm Birth

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease

Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma

Heart and Skeletal Muscle Problems in Neuroacanthocytosis

Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial

USDA Western Human Nutrition Research Center (WHNRC) Cross-Sectional Nutritional Phenotyping Study

Multimodal Immune and Neuroendocrine Assessment in Drinkers

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

Diet-Induced-Obesity Resistant Phenotypes in Humans

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

The Teaspoon Study - Telefitting Spinal Cord Stimulation for Pain

Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria